SelG1
Novartis in $665 million deal for Selexys
November 21, 2016Sales and Marketing Novartis, SelG1, selexys
Novartis have confirmed the acquisition of Selexys Pharmaceuticals, after Selexys received positive results from a Phase II trial. Novartis had …
Latest content
October 28, 2026
Acumentis CEO Herspiegel steps down as Burden assumes role
October 27, 2026
